SBC Medical's First Quarter Margins Improve; Company Announces Share Buyback Program
By Meg Flippin Benzinga
DETROIT, MICHIGAN - May 20, 2025 ( NEWMEDIAWIRE ) - SBC Medical Group Holdings Inc. (NASDAQ: SBC), the Japanese owner and operator of a chain of cosmetic surgery clinics, is in transformation mode, overhauling its pricing structure and adapting to a changing marketplace, which seems to have paid off in the company's first quarter.
For the three months ended March 31, 2025, SBC Medical reported earnings per share of $0.21, which was up 5% year-over-year. EBITDA margins were 52%, up from 46% in the year-ago first quarter.
The company, which is positioning itself as a leader in the cosmetic surgery market, ended the quarter with 251 clinics, increasing the number by 36 compared to last year's first quarter. Despite a challenging marketplace in Japan, SBC Medical was able to increase its customers in the last twelve months ending in March by 14% to 6.1 million. In a nod to the quality it offers customers at its clinics, SBC Medical also reported that 71% of customers visited franchisee clinics two or more times during the quarter.
'SBC is actively preparing for strategic expansion by enhancing its platform, optimizing its profitability structure, and stabilizing its business through revised pricing strategies and adapting to changing market dynamics,' said Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical, when reporting first quarter results. 'In the first quarter of 2025, we were pleased to see the expansion of Medical Corporations (MCs) gaining traction in our franchising, procurement and rental business segments as global demand for aesthetic medical services continued to rise.'
SBC Medical Group has been focused on expanding its MCs, which are designed to help cosmetic practitioners operate cosmetic surgery centers and at the same time adhere to regulations.
SBC Medical Overhauling For Growth
While SBC reported revenue of $47 million in the first quarter - down 14% year-over-year - the company attributed that to the discontinuation of its staffing business and the divestitures of Sky Net Academy and SBC Kijimadaira Resort. Despite that, margins increased, and net income increased 15% year-over-year. 'As we move ahead, we remain confident in our ability to build a scalable franchise model while accelerating expansion across domestic and international markets, driving long-term value for shareholders and positioning the Company to capitalize on future opportunities,' said Aikawa.
SBC Medical is working hard to position itself as a leader in the cosmetic surgery market, and it isn't resting on its laurels. To address competition and keep its leading position in the industry, the company is pursuing two strategies: expanding the market by making aesthetic medicine more accessible and appealing to the masses and differentiating itself from the competition by offering advanced treatments and better pricing - bringing its treatments to the U.S. and Singapore. The company is preparing for expansion and says its first quarter results are evidence of that.
Buying Back Shares
The company underscored its confidence in its growth plan by announcing its board has approved a share buyback program of up to $5 million worth of shares. The buyback program will kick off on May 20, 2025, and last through May 20, 2026.
The company is using excess cash and future free cash flow to buy back the shares. SBC Medical said it launched the program because it believes the stock at the current share price undervalues its business performance, growth potential and the aesthetic medical market, including SBC Medical's position. The global cosmetic surgery and procedure market was worth $122.08 billion in 2022, and it is expected to grow at a CAGR of 14.7% from 2023 to 2030.
SBC Medical will buy the shares on the open market at prevailing market prices and will continue to look at other ways to enhance the liquidity of its shares. It also plans to issue shares as future stock-based compensation in proportion to the number of repurchased shares. In addition to the repurchase program, SBC Medical says it will continue to consider dividend distributions with the goal of improving its total shareholder return.
From expanding the number of clinics to overhauling its pricing to lure new customers and repeat business, SBC Medical is positioning itself to capitalize on what it expects to be growth in the aesthetic medicine market. With a new stock buyback program underway, SBC Medical is showing the world and its investors it has confidence in its growth plans.
Featured image sourced fromShutterstock.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.
This content was originallypublished on Benzinga.Read further disclosureshere.
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Analysts assess the potential impact of Trump's surprise 50% steel tariffs
-- U.S. President Donald Trump unexpectedly announced on Friday that steel and aluminum tariffs will double to 50%. The move, set to come into effect on June 4, was unveiled during a campaign rally in Pennsylvania. It was later confirmed on TruthSocial and comes amid broader debates around U.S. industrial policy and foreign investment. Analysts are now evaluating the implications of this surprise decision, with most agreeing that the immediate domestic effects may be less severe than the broader geopolitical risks. JPMorgan's Tatsuya Maruyama said the direct impact on major Japanese steelmakers such as Nippon Steel Corp (TYO:5401), JFE Holdings, Inc. (TYO:5411), and Kobe Steel, Ltd. (TYO:5406) is expected to be limited, given that 'the U.S. accounts for about 4% of Japan's steel exports.' Maruyama pointed out in a Monday note that Nippon Steel and JFE export only about 1% of their total shipments to the U.S., while Kobe Steel exports about 3%. Still, he warned that 'rising global protectionism' is a growing concern, noting that a wave of anti-dumping measures and safeguards in regions like South Korea, the EU, and India could further strain global trade dynamics. 'If such countermeasures gain momentum, Japanese steel products may also be targeted and the export environment may worsen,' Maruyama continued. Meanwhile, analysts at BMO Capital Markets believe the sudden tariff hike could jolt domestic markets. 'The doubling of import tariffs, if maintained, is likely to create a panic in the market and trigger a restocking cycle that in our view has the potential to push prices >$1,000/st in the near-term,' the analysts said. However, they believe the spike would be temporary given macro uncertainty and seasonal demand trends. The broker upgraded Nucor (NYSE:NUE) to Outperform but downgraded Algoma Central (TSX:ALC), which it called 'a relative tariff loser.' The aluminum market may be more exposed, according to BMO. The U.S. covers only about 20% of its own aluminum consumption domestically, making it more vulnerable to supply disruptions. 'If tariffs do double, this is expected to put material upside pressure on the Midwest premium (MWP),' BMO wrote, estimating it could reach '$0.75/lb-plus' in theory, although higher aluminum cost will likely weigh on demand and thus offset some upside pressure. That said, the brokerage sees Century Aluminum (NASDAQ:CENX) as well positioned to benefit from a rise in the Midwest premium, while Alcoa (NYSE:AA) could see a negative impact of $1–2 per share, or 4–7%, due to its reliance on Canadian production. Still, BMO expects Alcoa may redirect some of its Canadian output to the EU market. Related articles Analysts assess the potential impact of Trump's surprise 50% steel tariffs Street Calls of the Week VIDEO: How to analyze a stock like a pro with the CEO of HF Foods
Yahoo
24 minutes ago
- Yahoo
1 Value Stock on Our Buy List and 2 to Approach with Caution
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues. Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. Keeping that in mind, here is one value stock with strong fundamentals and two best left ignored. Forward P/E Ratio: 14.5x Synonymous with "dad shoe", Skechers (NYSE:SKX) is a footwear company renowned for its comfortable, stylish, and affordable shoes for all ages. Why Is SKX Risky? Constant currency revenue growth has disappointed over the past two years and shows demand was soft Estimated sales growth of 7.4% for the next 12 months implies demand will slow from its two-year trend Poor free cash flow margin of 4.4% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends Skechers is trading at $62.04 per share, or 14.5x forward P/E. Dive into our free research report to see why there are better opportunities than SKX. Forward P/E Ratio: 9.9x Established in 1878, Mohawk Industries (NYSE:MHK) is a leading producer of floor-covering products for both residential and commercial applications. Why Are We Out on MHK? Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth ROIC of 3.5% reflects management's challenges in identifying attractive investment opportunities, and its decreasing returns suggest its historical profit centers are aging Diminishing returns on capital from an already low starting point show that neither management's prior nor current bets are going as planned At $100.61 per share, Mohawk Industries trades at 9.9x forward P/E. Check out our free in-depth research report to learn more about why MHK doesn't pass our bar. Forward P/E Ratio: 3.7x Pioneering treatments for a devastating childhood muscle-wasting disease that primarily affects boys, Sarepta Therapeutics (NASDAQ:SRPT) develops and commercializes RNA-targeted therapies and gene therapies for rare genetic disorders, primarily Duchenne muscular dystrophy. Why Are We Bullish on SRPT? Annual revenue growth of 51.3% over the last two years was superb and indicates its market share increased during this cycle Earnings per share grew by 38.8% annually over the last five years, massively outpacing its peers Cash burn has decreased over the last five years, showing the company is becoming a more self-sustaining business Sarepta Therapeutics's stock price of $37.50 implies a valuation ratio of 3.7x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
FTSE 100 LIVE: Markets slide as China accuses US of violating trade deal
The FTSE 100 (^FTSE) and European stocks slipped on Monday as China said the US "severely violated" the terms of their recent trade truce. Chinese officials said they would take strong measures to defend the country's interests. The two countries recently agreed to a 90-day moratorium after talks in Geneva, pledging to lower the tariffs on each other's goods. The US lowered its levy on imports from 145% to 30%, while China dropped its import tariff from 125% to 10%. China said the US had "seriously undermined" the agreement. The comments come after US president Donald Trump said on Friday that China had "totally violated its agreement with us". Beijing said violations included the US blocking sales of computer chip design software to Chinese companies and warning against the use of Chinese computer chips made by companies such as Huawei. They also said the US had cancelled visas for Chinese students. London's premier index fell 0.3%, having opened higher. Defence contractor Babcock International (BAB.L) rose the most, as the UK announced plans to build up a fleet of 12 attack submarines. Germany's DAX (^GDAXI) fell slightly, while the CAC 40 (^FCHI) was 0.2% lower. The pan-European STOXX 600 (^STOXX) was down 0.1%. Last week, Europe agreed its own stay of execution in trade negotiations with the US, pushing back the implementation of a 50% import tariff to July while talks continue on a possible deal. Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company to abandon the UK market for the US. However, the LSE welcomes Anglo-American's platinum spin-off Valterra after becoming independent from the mining giant. Indivior's exit comes after the company moved its primary listing to the US's Nasdaq index last year. It said cancelling the secondary listing in London eliminates 'cost and complexity' and better reflects the business – with more than 80% of its revenues generated in the US. It also said liquidity on the Nasdaq now 'far outweighs' that of the LSE with a greater level of trading. The US-based pharmaceutical firm makes prescription medicines to treat opioid addiction, and has a market capitalisation of £1.2bn. 'A single primary listing on Nasdaq best reflects the profile of Indivior's business,' chairman David Wheadon said. Here's Pedro Goncalves full take on UK house prices: Views from the market: Jonathan Hopper, CEO of Garrington Property Finders, said: CEO of Yopa, Verona Frankish, said: Tony Redondo, founder at Cosmos Currency Exchange said: House price growth edged up in May, according to Nationwide. Here are the headlines from their report: Annual rate of house price growth increased marginally in May to 3.5%, compared to 3.4% in April House prices were up 0.5% month on month House prices in predominantly rural areas have risen by 23% over the last five years, compared to 18% in more urban areas The average price in May was £273,427, compared with £270,752 in April. Robert Gardner, Nationwide's chief economist, said: Asian stocks traded lower on Monday as trade tensions, again, escalate between the US and China. US stock futures edged lower Monday morning, as investors turned the page on a bullish May and eyed the month ahead with trade uncertainty lingering. S&P 500 futures (ES=F) were down 0.4%, as futures tied to the Dow Jones Industrial Average (YM=F) sank 0.5%. Contracts tied to the Nasdaq 100 (NQ=F) slipped 0.6%. The tepid start to June follows a standout May: The S&P 500 (^GSPC) rallied more than 6% in its best month since November 2023 and best May since 1990. The Nasdaq Composite (^IXIC) soared 9%, and the Dow (^DJI) notched a 4% gain. Tech stocks led the charge, as investor optimism around AI and resilient economic data fuelled risk appetite. Read more on Yahoo Finance Hello from London. Lucy Harley-McKeown here, ready to bring you the markets and business news of the day. We have a few diary items to start us off: PMI releases for the EU, UK and US Nationwide's house price index The monthly money and credit report from the Bank of England In the US, corporate results from Campbell Soup (CPB). Let's get to it. Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company to abandon the UK market for the US. However, the LSE welcomes Anglo-American's platinum spin-off Valterra after becoming independent from the mining giant. Indivior's exit comes after the company moved its primary listing to the US's Nasdaq index last year. It said cancelling the secondary listing in London eliminates 'cost and complexity' and better reflects the business – with more than 80% of its revenues generated in the US. It also said liquidity on the Nasdaq now 'far outweighs' that of the LSE with a greater level of trading. The US-based pharmaceutical firm makes prescription medicines to treat opioid addiction, and has a market capitalisation of £1.2bn. 'A single primary listing on Nasdaq best reflects the profile of Indivior's business,' chairman David Wheadon said. Here's Pedro Goncalves full take on UK house prices: Views from the market: Jonathan Hopper, CEO of Garrington Property Finders, said: CEO of Yopa, Verona Frankish, said: Tony Redondo, founder at Cosmos Currency Exchange said: House price growth edged up in May, according to Nationwide. Here are the headlines from their report: Annual rate of house price growth increased marginally in May to 3.5%, compared to 3.4% in April House prices were up 0.5% month on month House prices in predominantly rural areas have risen by 23% over the last five years, compared to 18% in more urban areas The average price in May was £273,427, compared with £270,752 in April. Robert Gardner, Nationwide's chief economist, said: Asian stocks traded lower on Monday as trade tensions, again, escalate between the US and China. US stock futures edged lower Monday morning, as investors turned the page on a bullish May and eyed the month ahead with trade uncertainty lingering. S&P 500 futures (ES=F) were down 0.4%, as futures tied to the Dow Jones Industrial Average (YM=F) sank 0.5%. Contracts tied to the Nasdaq 100 (NQ=F) slipped 0.6%. The tepid start to June follows a standout May: The S&P 500 (^GSPC) rallied more than 6% in its best month since November 2023 and best May since 1990. The Nasdaq Composite (^IXIC) soared 9%, and the Dow (^DJI) notched a 4% gain. Tech stocks led the charge, as investor optimism around AI and resilient economic data fuelled risk appetite. Read more on Yahoo Finance Hello from London. Lucy Harley-McKeown here, ready to bring you the markets and business news of the day. We have a few diary items to start us off: PMI releases for the EU, UK and US Nationwide's house price index The monthly money and credit report from the Bank of England In the US, corporate results from Campbell Soup (CPB). Let's get to it. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
